Evaluation of POLE and POLD1 Mutations as Biomarkers for Immunotherapy Outcomes Across Multiple Cancer Types

Feng Wang, MD, PhD, Qi Zhao, PhD, Ying-Nan Wang, MD, PhD, Ying Jin, MD, PhD, Ming-Ming He, MD, PhD, Ze-Xian Liu, MD, PhD, and Rui-Hua Xu, MD

Jama Oncology, 2019 Aug 15

Abstract Link